col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


236 Results       Page 1

 [1] 
Wiley: British Journal of Dermatology
  original article Date Title Authors   All Authors
1 [GO] 2026―Jun―26 LY16 Primary cutaneous follicle centre lymphoma arising at a COVID-19 vaccination site with spontaneous regression Ciara Devenney, Fiona Sexton, Kevin Molloy
2 [GO] 2026―Jun―04 Melanoma diagnosis during COVID-19: delay, disruption and the question of overdiagnosis Aram Boada, Antonio Tejera-Vaquerizo
3 [GO] 2026―May―01 Evaluating COVID-19 Pandemic Impact on Melanoma Incidence and factors in Regions with Different Infection Control Strategies Cecilia Sand, Dilki Jayasinghe, Rory Wolfe, Victoria Mar, Karolin Isaksson, Åsa Ingvar
4 [GO] 2025―Jul―03 Can the effects of the COVID-19 pandemic provide insights into the impact of melanoma under-diagnosis and delayed care? Dimitrios Karponis, Khaylen Mistry, Giannis Stratigos, Nick J Levell, Alexander J Stratigos, Vasiliki Nikolaou, Zoe C Venables
5 [GO] 2025―Jun―27 P074 Pemphigus vulgaris management after COVID-19: challenges of low- and middle-income countries Amna Khalid, Atiya Rahman
6 [GO] 2025―Jun―27 P108 Association between COVID-19 vaccines and bullous pemphigoid: a UK population-based study Mikolaj Swiderski, Yana Vinogradova, Matthew J Ridd, Zenas Z N Yiu, Antonia Lloyd-Lavery, Vibhore Prasad, Sonia Gran
7 [GO] 2025―Jun―27 P107 Association between the COVID-19 vaccination programme and incidence rates of bullous pemphigoid, herpes zoster and urticaria in the UK: an interrupted time series analysis Mikolaj Swiderski, Sarah Lewis, Yana Vinogradova, Matthew J Ridd, Zenas Z N Yiu, Antonia Lloyd-Lavery, et al. (+2)
8 [GO] 2025―Jun―27 P147 Exploring the impact of age and deprivation on malignant melanoma diagnoses during the COVID-19 pandemic in England: a national retrospective cohort study Lena Ibrahim, Birgitta van Bodegraven, Nick J Levell, Zoe C Venables
9 [GO] 2025―Jun―19 Incidence rates of bullous pemphigoid, herpes zoster and urticaria following the start of the COVID-19 vaccination programme in the UK: a population-based cohort study Mikolaj Swiderski, Sarah Lewis, Yana Vinogradova, Matthew J Ridd, Zenas Z N Yiu, Antonia Lloyd-Lavery, et al. (+2)
10 [GO] 2024―Dec―10 P08 Study on the impact of COVID-19 infection in patients with moderate-to-severe plaque psoriasis on biologics: a tertiary centre experience in India
11 [GO] 2024―Dec―10 P37 Humoral immunity to mRNA-based COVID-19 vaccines after a booster dose in patients with psoriasis receiving immunomodulatory therapy
12 [GO] 2024―Dec―10 P114 Deucravacitinib treatment did not affect immune response to SARS-Cov-2 vaccines and infection in patients with plaque psoriasis: results from the Phase 3 POETYK long-term extension trial
13 [GO] 2024―Jun―28 P076 Risk of psoriatic arthritis and uveitis among patients with psoriasis after COVID-19 infection: a nationwide cohort study Tai-Li Chen, Chen-Yi Wu, Wei-Chuen Chang, Chih-Chiang Chen
14 [GO] 2024―Jun―28 DP08 Striking post COVID-19 vaccine aseptic pustular folliculitis, a follicular variant of acute generalized exanthematous pustulosis Nikesh Patel, Natalie King-Stokes, Jonathan Carter, Richard Carr
15 [GO] 2024―Jun―28 BG08 Boosting the cutaneous chronicle of the COVID-19 vaccine: it’s not over yet Emily Moon, Chenjing Peng, Anthony Abdullah
16 [GO] 2024―Jun―28 BT19 The rising dermatology advice and guidance pandemic: building a workforce group with nationally implantable solutions that led to significant improvements over a 10-week period Charankumal Singh Thandi, Jake Moss, Margaret Andrews
17 [GO] 2024―Jun―28 O13 42 590 fewer skin tumours diagnosed in England during the 2020 COVID pandemic: greatest reductions in melanoma in situ, stage I melanomas and basal cell carcinomas Omsin Srimudkul, Zoe C Venables, Nick J Levell, Khaylen Mistry, Birgitta Van Bodegraven
18 [GO] 2023―Dec―01 Maternal SARS-CoV-2 infection during pregnancy and subsequent risk of atopic dermatitis in offspring: a nationwide birth cohort study in South Korea Minji Kim, Yujin Choi, Myeongcheol Lee, Jiseung Kang, So Min Kang, Dong-Geol Lee, Dong Keon Yon
19 [GO] 2023―Oct―27 Career advancement for female academic dermatologists: how the pandemic exacerbated inequities, and the path forward Ramneek K Dhami, Justin W Ng, Erin L Foster, Emile Latour, Jesse J Keller
20 [GO] 2023―Oct―02 Melanoma incidence and COVID-19 lockdowns in the Netherlands Philippe Autier
21 [GO] 2023―Aug―25 O01 Clinical aspects of psoriasis flares and risk factors for developing a post-infectious flare in children with SARS-CoV-2 infection: data from the Chi-PsoCov registry Emmanuel Mahé, Vito di Lernia, Anna Belloni Fortina, Aleksandra Lesiak, Piotr Brzezinski, Zeynep Topkarci, et al. (+18)
22 [GO] 2023―Aug―25 P06 Atopic dermatitis and psoriasis in children, and SARS-CoV-2 infection: different impact of the infection on these dermatoses, and of these dermatoses on the infection? Emmanuel Mahé, Jinane Zitouni, Maud Amy de la Breteque
23 [GO] 2023―Jul―18 The impact of biologic therapy for moderate-to-severe psoriasis on the immune responses to SARS-CoV2 infection and vaccination Rebecca Favaro, Alessandra Formai, Giulia Pavia, Luigi Gargiulo, Jessica Avagliano, Mario Valenti, et al. (+7)
24 [GO] 2023―Jun―28 Bidirectional Mendelian randomization analysis did not indicate a causal relationship between atopic dermatitis and COVID-19 Min Luo, Changhua Zhu, Jinger Lin, Lihang Lin, Yue Han
25 [GO] 2023―Jun―26 BT04 Efficient triaging of advice and guidance referrals using teledermatology via the National Health Service Electronic Referral System platform: reporting positive outcomes from the COVID-19 era Anthoula Efstathiadou, Kellen Beck-Sander, Wen Ai Woo, Hywel Cooper, Charles Mitchell
26 [GO] 2023―Jun―26 DP07 The effect of the COVID-19 pandemic on the Breslow thickness of melanoma at presentation Eva Lau, Joanne Bowers, Katherine Humphris, Louise Binns, Benjamin Walker, Alison Layton
27 [GO] 2023―Jun―26 P32 Impact of the COVID-19 pandemic on health equality in malignant melanoma diagnosis Kenny Lau, Huan Cheng, Rima Hussain
28 [GO] 2023―Jun―26 P15 Progressive papulonodular eruption following COVID-19 infection: a rare diagnosis and review of the literature Rhian Sheppeard, Stephanie Austin, Caroline Morgan, Margaret Ashton-Key
29 [GO] 2023―Jun―26 P28 Impact of the COVID-19 pandemic on cutaneous squamous cell carcinoma pathology reports in England and its nine regions: 1127 fewer cSCCs reported in 2020 compared with that in 2019 James Wall, Zoe Venables, Nick Levell
30 [GO] 2023―Jun―26 P09 A case of suspected COVID-19 vaccine-induced antiphospholipid syndrome Patrick Bryan, Namor Williams, Geraldine Haebich
31 [GO] 2023―May―21 Hidradenitis suppurativa patient-reported influences on COVID-19 vaccine acceptance and hesitancy Jazzmin C Williams, Raed Alhusayen, Sandra Guilbault, John R Ingram, Michelle A Lowes, Christine A Yannuzzi, Haley B Naik
32 [GO] 2023―May―03 COVID-19 and the skin, three years on: long term impacts, emerging trends and clinical practice Esther E Freeman, Ignacio Garcia-Doval, Luigi Naldi, Rod J Hay
33 [GO] 2023―Apr―20 Immunity 6 months after COVID-19 vaccination in patients with psoriasis treated with immunomodulatory drugs
34 [GO] 2023―Apr―10 Missing melanomas in England during the COVID-19 pandemic: 2,485 fewer melanoma diagnoses in 2020 than in 2019 Lena S Ibrahim, Zoe C Venables, Sean McPhail, Nick J Levell
35 [GO] 2023―Feb―10 Responses to AstraZeneca COVID-19 vaccines in patients with immune-mediated skin diseases
36 [GO] 2023―Jan―27 Waning humoral and cellular immunity after COVID-19 vaccination in patients with psoriasis treated with methotrexate and biologics: a cohort study Amanda Kvist-Hansen, Laura Pérez-Alós, Rownaq Fares Al-Sofi, Line Dam Heftdal, Sebastian Rask Hamm, Dina Leth Møller, et al. (+16)
37 [GO] 2023―Jan―20 Is vaccination against COVID-19 associated with psoriasis or eczema flare? Self-controlled case series analysis using data from the Clinical Practice Research Datalink (Aurum) Laura Adams, Georgina Nakafero, Matthew J Grainge, Tim Card, Christian D Mallen, Jonathan S Nguyen Van-Tam, et al. (+2)
38 [GO] 2023―Jan―20 Non-adherence to systemic immune-modifying therapy in people with psoriasis during the COVID-19 pandemic: findings from a global cross-sectional survey Sophia Quirke-McFarlane, John Weinman, Emma S Cook, Zenas Z N Yiu, Nick Dand, Sinead M Langan, et al. (+33)
39 [GO] 2023―Jan―20 Psoriasis treatment does not impair the immunogenicity of ChAOx1-S[recombinant] COVID-19 vaccination Lluís Puig
40 [GO] 2023―Jan―19 Non-adherence to immune-modifying therapies during Covid-19 pandemic: the crucial role of doctor-patient communication to avoid drug discontinuation Mario Valenti, Antonio Costanzo
41 [GO] 2023―Jan―08 Failure to detect SARS-CoV-2 in the sweat of COVID-19 patients at RNA and protein level Thilo Gambichler, Silke Goesmann, Vera Korte, Marina Skrygan, Friederike Harnischfeger, Christina H Scheel, et al. (+5)
42 [GO] 2022―Aug―16 COVID-19 pandemic associated chilblains. More link for SARS-CoV-2 and less evidence for high interferon type-1 systemic response Didier Bessis, Sophie Trouillet-Assant, Léo-Paul Secco, Nathalie Bardin, Brigitte Blanc, Véronique Blatière, et al. (+18)
43 [GO] 2022―Aug―02 Nailfold videocapillaroscopy and serum VEGF in probable COVID-19-induced chilblains: a cross-sectional study to assess microvascular impairment Yora Mostmans, Vanessa Smith, Maurizio Cutolo, Karin Melsens, Salomé Battist, Asma Benslimane, et al. (+4)
44 [GO] 2022―Jul―23 Cutaneous Manifestations of SARS-CoV -2 infection during the Delta and Omicron waves in 348,691 UK users of the UK ZOE COVID Study App Alessia Visconti, Benjamin Murray, Niccolò Rossi, Jonathan Wolf, Sebastien Ourselin, Tim D. Spector, et al. (+3)
45 [GO] 2022―Jul―06 P02: Toxic epidermal necrolysis after COVID-19 booster vaccination: is a mixed vaccination schedule a risk?
46 [GO] 2022―Jul―06 GIRFT01: The long-term costs of COVID-19 for patients with skin cancer: a retrospective single-centre review of multidisciplinary team skin cancer cases and outcomes from 2019 to 2021
47 [GO] 2022―Jul―06 P11: Leser-Trélat sign: can it follow COVID-19 infection?
48 [GO] 2022―Jul―06 RF02: Hospitalization from COVID-19 is most frequently observed in patients with atopic dermatitis treated with systemic corticosteroids, and in particular when systemic corticosteroids are used in combination with another immunomodulatory treatment: lessons from the global SECURE-AD registry
49 [GO] 2022―Jul―06 GIRFT03: The number needed to treat metric: a further marker of the impact of COVID-19 on malignant melanomas
50 [GO] 2022―Jul―06 O02: Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform
51 [GO] 2022―Jul―06 P24: Benzalkonium chloride: a potential emerging allergen in the era of the COVID-19 pandemic
52 [GO] 2022―Jul―06 P19: Fast-track occupational health dermatology clinic for healthcare workers: trends and burden of occupational dermatoses during the COVID-19 pandemic
53 [GO] 2022―Jul―06 P49: A comparative analysis of cutaneous squamous cell carcinoma staging before and during the COVID-19 pandemic.
54 [GO] 2022―Jul―06 GIRFT02: The influence of the COVID-19 pandemic on Breslow thickness and outpatient malignant melanoma service provision in an Irish Dermatology centre
55 [GO] 2022―Jul―06 P47: Effects of the COVID-19 pandemic on quality of utilization of the 2-week wait skin cancer pathway
56 [GO] 2022―Jul―06 P42: Clinical, histopathological and dermatoscopic characterization of eruptive pseudoangioma developing after COVID-19 vaccination
57 [GO] 2022―Jul―06 P29: COVID-19 vaccination and leprosy: a UK hospital-based retrospective cohort study
58 [GO] 2022―Jul―06 P46: A case series of COVID-19 vaccination and lymphatic dysfunction
59 [GO] 2022―Jul―06 CPC08: New-onset pemphigus foliaceus following COVID-19 vaccine
60 [GO] 2022―Jul―06 CPC02: An unusual case of rash secondary to the COVID-19 vaccine is presented with a review of the literature
61 [GO] 2022―Jul―06 P04: Phototherapy to treat a COVID-19 vaccine reaction
62 [GO] 2022―Jul―06 CD15: The development of a semi-virtual patch testing service at a university hospital during the COVID -19 pandemic
63 [GO] 2022―Jul―06 BI05: Is a hybrid skin cancer surveillance service for organ transplant recipients feasible? Lessons from the pandemic
64 [GO] 2022―Jul―06 PA08: Survey of caregiver satisfaction with remote versus face-to-face consultations in a tertiary paediatric dermatology clinic during the COVID -19 pandemic
65 [GO] 2022―Jul―06 H19: Plica polonica: a Polish pandemic
66 [GO] 2022―Jul―06 BT23: The impact of the COVID -19 pandemic and use of teledermatology in specialty training: experience at two UK dermatology training centres
67 [GO] 2022―Jul―06 BT17: A 3-year review of an innovative teledermatology service in paediatric dermatology delivering results in the face of a pandemic backlog
68 [GO] 2022―Jul―06 DP17: Impact of the COVID -19 pandemic on melanoma staging in a Scottish health board
69 [GO] 2022―Jul―06 BT03 (P47): Effects of the COVID -19 pandemic on quality of utilization of the 2-week wait skin cancer pathway
70 [GO] 2022―Jul―06 BT24: The effect of the COVID -19 pandemic on teledermatology usage and practices in a major secondary care centre
71 [GO] 2022―Jul―06 DS07: Missing melanomas in England during the COVID -19 pandemic: 2488 fewer melanoma diagnoses in 2020 than in 2019
72 [GO] 2022―Jul―06 H07: A historical review of pandemics with a dermatological perspective
73 [GO] 2022―Jun―14 Drug reaction with eosinophilia and systemic symptoms in patients hospitalized with Coronavirus Disease 2019: A case series from a large United States healthcare system Bethany Cucka, Bianca Biglione, Li Zhou, Elizabeth J. Phillips, Fatima Bassir, Upeka Samarakoon, et al. (+6)
74 [GO] 2022―Jun―02 Sweet-like syndrome and Multiple COVID-Arm syndrome following COVID-19 vaccines: “Specific” patterns in a series of 192 patients Anne-Sophie Darrigade, Bénédicte Oulès, Pierre Sohier, Marie-Laure Jullie, Philippe Moguelet, Annick Barbaud, et al. (+8)
75 [GO] 2022―Jun―02 Pernio and Early SARS-CoV-2 Variants: Natural History of a Prospective Cohort and the Role of Interferon Ashley T. Ng, John J. Moon, Olivia R. Steidl, Hailey Bussan, Jennifer M. Tran, George Luong, et al. (+10)
76 [GO] 2022―May―25 Heterogeneity of reports about the impact of the COVID -19 pandemic on melanoma diagnosis Francesco Ricci, Damiano Abeni
77 [GO] 2022―Feb―01 Vaccine hesitancy and access to psoriasis care in the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey Katie Bechman, Emma S. Cook, Nick Dand, Zenas Z.N. Yiu, Teresa Tsakok, Freya Meynell, et al. (+33)
78 [GO] 2022―Jan―27 Examining the Risk of Breakthrough Infection and COVID-19 Vaccination Safety in Atopic Dermatitis Patients Haig Pakhchanian, Rahul Raiker, Melanie Wolf, Shannon C. Trotter
79 [GO] 2022―Jan―06 Do treatments for psoriasis increase the risk of hospital admission or death caused by COVID-19 infections?
80 [GO] 2022―Jan―06 Varied skin reactions after COVID-19 vaccination
81 [GO] 2021―Dec―17 Chilblain-like lesions during the COVID-19 outbreak
82 [GO] 2021―Nov―29 COVID-19 vaccine acceptance and hesitancy in patients with immunobullous diseases: a cross-sectional study of the International Pemphigus and Pemphigoid Foundation M. Kasperkiewicz, R. Strong, K. Mead, M. Yale, D. Zillikens, D.T. Woodley, A. Recke
83 [GO] 2021―Nov―25 Bullous Sweet syndrome following SARS-CoV-2 Oxford AstraZeneca vaccine T. Žagar, N. Hlača, I. Brajac, L. Prpić-Massari, S. Peternel, M. Kaštelan
84 [GO] 2021―Nov―13 Bullous pemphigoid after SARS-CoV-2 vaccination: Spike protein-directed immunofluorescence confocal microscopy and T cell receptor studies T. Gambichler, N. Hamdani, H. Budde, M. Sieme, M. Skrygan, L. Scholl, et al. (+10)
85 [GO] 2021―Nov―08 Should we look beyond the interferon signature in chilblain-like lesions associated with COVID-19? S.M. Pilkington, R.E.B. Watson
86 [GO] 2021―Nov―02 Administrative data and scientific evidence: a lesson from France - the safety of systemic treatment for psoriasis during the COVID-19 pandemic S. Cazzaniga, L. Naldi
87 [GO] 2021―Nov―02 COVID-19 vaccines and skin manifestations V. Bataille, S. Puig
88 [GO] 2021―Nov―02 Bilateral giant cell arteritis with skin necrosis following SARS-CoV-2 vaccination T. Gambichler, C. Krogias, I. Tischoff, A. Tannapfel, R. Gold, L. Susok
89 [GO] 2021―Oct―08 Type I interferon response and vascular alteration in chilblain-like lesions during the COVID-19 outbreak L. Frumholtz, J.-D. Bouaziz, M. Battistella, J. Hadjadj, R. Chocron, D. Bengoufa, et al. (+24)
90 [GO] 2021―Oct―06 Occupational dermatoses during the second COVID-19 pandemic wave: a UK prospective study of 805 healthcare workers J. M. Gao, R. Goiriz, S. Rajpopat, P. Goldsmith
91 [GO] 2021―Sep―29 A case of COVID-19 vaccination-associated forme fruste purpura fulminans J. Griss, S. Eichinger, S. Winkler, W. Weninger, P. Petzelbauer
92 [GO] 2021―Aug―24 Not relevant responses in the era of Covid-19 - are we underestimating dermatology life quality index values? N. Kearney, R. Hambly, A. Alsharqi, B. Kirby
93 [GO] 2021―Aug―16 Sunlight separately from vitamin D is associated with a lower risk of death from COVID-19
94 [GO] 2021―Jul―26 Psoriasis-related treatment exposure and hospitalization or in-hospital mortality due to COVID-19 during the first and second wave of the pandemic: cohort study of 1,326,312 patients in France L. Penso, R. Dray-Spira, A. Weill, M. Zureik, E. Sbidian
95 [GO] 2021―Jul―14 Analysis of T cell responses directed against the spike and/or membrane and/or nucleocapsid proteins in chilblain-like lesions patients during the COVID-19 pandemic C. Cassius, M. Merandet, L. Frumholtz, D. Bergerat, A. Samri, C. Grolleau, et al. (+10)
96 [GO] 2021―Jul―13 Cutaneous reactions after SARS-COV-2 vaccination: A cross-sectional Spanish nationwide study of 405 cases A. Català, C. Muñoz-Santos, C. Galván-Casas, M. Roncero Riesco, D. Revilla Nebreda, A. Solá-Truyols, et al. (+34)
97 [GO] 2021―Jul―06 GIRFT06: Dermatology high-cost drug management: pharmacists getting it right first time in COVID-19
98 [GO] 2021―Jul―06 DS26: COVID-19 and reduced detection of malignant melanoma in secondary dermatology services
99 [GO] 2021―Jul―06 DT04: Pandemic placement: delivering the dermatology undergraduate curriculum at a UK medical school during the COVID-19 crisis
100 [GO] 2021―Jul―06 BT10: Medical education in the COVID-19 era: a remote dermatology attachment
101 [GO] 2021―Jul―06 DS06: Contending with COVID-19 in a Mohs micrographic surgery service
102 [GO] 2021―Jul―06 P19: Cutaneous manifestations of COVID-19 in the UK: a registry of digital submissions from interdisciplinary healthcare professionals
103 [GO] 2021―Jul―06 DP16: Severe, ulcerative cold panniculitis following COVID-19 infection
104 [GO] 2021―Jul―06 DP08: Leprosy unmasked by COVID-19 infection: a new diagnosis of leprosy with development of type 1 reversal reaction
105 [GO] 2021―Jul―06 DS25: Pandemic pressures: the impact of COVID-19 on the 2-week-wait service at a regional skin oncology centre
106 [GO] 2021―Jul―06 P28: The effects of COVID-19 on undergraduate dermatology training: a qualitative study
107 [GO] 2021―Jul―06 BT19: The use of a novel teledermatology/teledermoscopy service to maintain a dermatology cancer service in the midst of the COVID-19 pandemic
108 [GO] 2021―Jul―06 BT18: A new era for teledermatology in the COVID-19 pandemic
109 [GO] 2021―Jul―06 BT16: Disaster-recovery modelling to shape services: a dermatology helpline as a telemedicine intervention during the initial surge of the COVID-19 pandemic
110 [GO] 2021―Jul―06 PD11: Access to phototherapy during the COVID-19 pandemic
111 [GO] 2021―Jul―06 BT14: Exploring the feasibility of a remote acne service: a report of a pilot study using the MySkinSelfie platform during the COVID-19 pandemic
112 [GO] 2021―Jul―06 BT09: Standard of patient-sent images in teledermatology 2-week-wait skin cancer clinics during the COVID-19 pandemic
113 [GO] 2021―Jul―06 BI08: Remote management of immunotherapy-induced bullous pemphigoid during the COVID-19 pandemic
114 [GO] 2021―Jul―06 DS14: Experience of using a scar-assessment tool to evaluate scars after Mohs surgery via virtual consultation during the COVID-19 pandemic
115 [GO] 2021―Jul―06 P57: Surprising trends in the detection of cutaneous malignancy during the COVID-19 pandemic
116 [GO] 2021―Jul―06 BT15: Evaluating paediatric dermatology telephone clinics during the COVID-19 pandemic in a UK cohort: a prospective study
117 [GO] 2021―Jul―06 DS23: A multicentre qualitative study of patients’ experience of skin surgery during the COVID-19 pandemic in the UK
118 [GO] 2021―Jul―06 DT07: The impact of the COVID-19 pandemic on dermatology ST3 application preparation: a national survey of junior doctors in the UK
119 [GO] 2021―Jul―06 BI07: The effect of the COVID-19 pandemic on immunosuppressed patients undergoing skin surveillance
120 [GO] 2021―Jul―06 O01: The impact of the COVID-19 pandemic on people with psoriasis: findings from a global patient-reported registry
121 [GO] 2021―Jul―06 P25: The impact of the second wave of the COVID-19 pandemic on the quality of life of patients with skin cancer
122 [GO] 2021―Jul―06 CD08: Occupational dermatoses during the second COVID-19 pandemic wave: an audit of 401 healthcare workers
123 [GO] 2021―Jul―06 P38: Mental health of patients with psoriasis during the COVID-19 pandemic: a cross-sectional study in a tertiary setting
124 [GO] 2021―Jul―06 PS06 (P38): Mental health of patients with psoriasis during the COVID-19 pandemic: a cross-sectional study in a tertiary setting
125 [GO] 2021―Jul―06 BT12: The environmental impact of teledermatology in the COVID-19 pandemic: a silver lining
126 [GO] 2021―Jul―06 CD07: A survey of the incidence of skin problems in a cohort of hospital staff during the COVID-19 pandemic: can this help plan future services?
127 [GO] 2021―Jul―06 DT03: Diversifying educational resources during the COVID-19 pandemic: delivering educational dermatology podcasts and webinars for healthcare professionals
128 [GO] 2021―Jul―06 BT04: A new virtual inpatient dermatology electronic referral service: a timely answer to reducing cross-contamination during the COVID-19 pandemic?
129 [GO] 2021―Jul―06 DT02: What has been the impact of COVID-19 redeployment on dermatology trainees’ professional identity? An interpretative phenomenological study
130 [GO] 2021―Jul―06 P21: Practising dermatology in the era of COVID-19: a tertiary centre’s experience of adapting to change
131 [GO] 2021―Jul―06 PD14: Treating field cancerization in a time of COVID-19: daylight photodynamic therapy is effective, socially distant and satisfactory to our most vulnerable patients
132 [GO] 2021―Jul―06 P46: Occupational dermatoses during COVID-19: effect on work and wellbeing
133 [GO] 2021―Jul―06 P62: An increase in Breslow thickness: coronavirus or coincidence?
134 [GO] 2021―Jul―06 PD05: Skin safety and efficacy of filtered far ultraviolet C for SARS-CoV-2 inactivation
135 [GO] 2021―Jul―06 CD09: A review of semi-virtual patch testing during the SARS-CoV-2 pandemic: practicalities and patient experience
136 [GO] 2021―Jul―06 Primary cutaneous anaplastic large cell lymphoma with marked spontaneous regression of organ manifestation after SARS-CoV-2 vaccination T. Gambichler, S. Boms, S. Hessam, I. Tischoff, A. Tannapfel, T. Lüttringhaus, et al. (+2)
137 [GO] 2021―Jul―06 P24: Dermatology medical student history taking via the telephone: a way to minimize disruption to medical education, particularly during a pandemic
138 [GO] 2021―Jul―06 P73: A novel approach to systemic monitoring in a pandemic
139 [GO] 2021―Jul―05 Yet another benefit from sunlight in the fight against COVID-19? R.L. McKenzie, J.B. Liley
140 [GO] 2021―Jul―03 在 2019 年新型冠状病毒疾病 (COVID-19) 疫情期间, 银屑病或关节病患者的隔离因治疗类型而异
141 [GO] 2021―Jul―03 Shielding behaviour in people with psoriasis or a joint condition during the COVID-19 pandemic differs by treatment type
142 [GO] 2021―Jun―15 Relapse of chilblain-like lesions during the second COVID-19 pandemic wave: a cohort follow-up T. Hubiche, F. Le Duff, E. Fontas, J. Rapp, C. Chiaverini, T. Passeron
143 [GO] 2021―Jun―11 Kawasaki-like Multisystem Inflammatory Syndrome Associated with Coronavirus disease 2019 in an Adult: A case report R. Dabas, G. Varadaraj, S. Sandhu, A. Bhatnagar, R. Pal
144 [GO] 2021―Jun―09 COVID-19 outcomes in patients with autoimmune blistering disease E. Hwang, M.M. Tomayko
145 [GO] 2021―May―25 COVID-19-associated multisystem inflammatory syndrome in adults with Kawasaki disease-like cutaneous manifestations M. Razmi T, T.P. Afra, T.P. Mohammed, P.T.M. Ashik, E. Sukesh
146 [GO] 2021―May―20 Forewarned is Forearmed: chronic spontaneous urticaria as a potential risk to effective SARS-COV-2 vaccine uptake and global public health W.H. Bermingham, M.R. Ardern-Jones, A.P. Huissoon, M.T. Krishna
147 [GO] 2021―May―19 Skin checks and skin cancer diagnosis in Australian general practice before and during the COVID pandemic, 2011-2020 J. Roseleur, D.A. Gonzalez-Chica, J. Emery, N.P. Stocks
148 [GO] 2021―May―17 Rarity of cutaneous findings among asymptomatic to mildly symptomatic COVID-19 patients admitted to a COVID Care facility in Delhi, India: An observational study A. Khurana, A. Mittal, R. Jain, A. Mishra, S.R. Mathachan
149 [GO] 2021―May―13 Antibody responses to single-dose SARS-CoV-2 vaccination in patients receiving immunomodulators for immune-mediated inflammatory disease A. Al-Janabi, Z. Littlewood, C.E.M. Griffiths, H.J.A. Hunter, H. Chinoy, C. Moriarty, et al. (+2)
150 [GO] 2021―May―07 SARS-CoV-2 infection in patients with atopic dermatitis: a cross-sectional study C. Nguyen, K. Yale, F. Casale, A. Ghigi, K. Zheng, J.I. Silverberg, N.A. Mesinkovska
151 [GO] 2021―May―06 Psoriasis, COVID-19 and shielding G. Becher, A.D. Burden
152 [GO] 2021―May―05 Diagnosis of COVID-19 using skin rashes
153 [GO] 2021―May―03 The impact of the COVID-19 pandemic on skin cancer incidence and treatment in England, 2020 Z.C. Venables, S. Ahmed, T. Bleiker, J. Broggio, M. Kwiatkowska, N.J. Levell, et al. (+6)
154 [GO] 2021―Apr―27 Chilblain lesions after COVID-19 mRNA vaccine A. Pileri, A. Guglielmo, B. Raone, A. Patrizi
155 [GO] 2021―Apr―27 Pityriasis rosea-like eruption after Pfizer-BioNTech COVID-19 vaccination A.M. Carballido Vázquez, B. Morgado
156 [GO] 2021―Apr―24 Pernio after COVID-19 Vaccination S. Lopez, P. Vakharia, T. Vandergriff, E.E. Freeman, R. Vasquez
157 [GO] 2021―Apr―10 Outcomes of COVID-19 in Patients with Skin Cancer R. Raiker, H. Pakhchanian, A. Hussain, M. Deng
158 [GO] 2021―Apr―09 Ultraviolet A Radiation and COVID-19 Deaths in the USA with replication studies in England and Italy M. Cherrie, T. Clemens, C. Colandrea, Z. Feng, D.J. Webb, R.B. Weller, C. Dibben
159 [GO] 2021―Mar―18 Recurrence of chilblains during a second contact with SARS-CoV-2: a case report S. Maanaoui, F. Salez, O. Carpentier
160 [GO] 2021―Mar―17 Risk of COVID-19 infection in adult patients with atopic eczema and psoriasis: a single centre, cross-sectional study Z.Z.N. Yiu, G. Harding, C.E.M. Griffiths, R.B. Warren, E. McMullen, H.J.A. Hunter
161 [GO] 2021―Mar―04 The skin as a target for SARS-CoV-2 infection: exploiting the web for suitable data L. Naldi
162 [GO] 2021―Mar―03 Cold and COVID: Recurrent Pernio during the COVID-19 Pandemic E.E. Freeman, D.E. McMahon, J.B. Lipoff, M. Rosenbach, S.R. Desai, M. Fassett, et al. (+4)
163 [GO] 2021―Feb―20 Intention of COVID-19 vaccination among psoriatic patients compared to immunosuppressed patients with other skin diseases and factors influencing their decision E. Sotiriou, K. Bakirtzi, I. Papadimitriou, E. Paschou, E. Vakirlis, A. Lallas, D. Ioannides
164 [GO] 2021―Feb―08 与 COVID-19 相关的皮肤疾病以及相关生物制剂
165 [GO] 2021―Feb―08 Association of COVID-19 with skin diseases and relevant biologics
166 [GO] 2021―Jan―29 SARS-CoV-2 Spike Protein Positivity in Pityriasis Rosea-like and Urticaria-like Rashes of COVID-19 E. Welsh, J.A. Cardenas-de la Garza, A. Cuellar-Barboza, R. Franco-Marquez, R.I. Arvizu-Rivera
167 [GO] 2021―Jan―17 Oral ivermectin for a scabies outbreak in a long-term-care facility: Potential value in preventing COVID-19 and associated mortality? C. Bernigaud, D. Guillemot, A. Ahmed-Belkacem, L. Grimaldi-Bensouda, A. Lespine, F. Berry, et al. (+6)
168 [GO] 2021―Jan―15 Diagnostic value of cutaneous manifestation of SARS-CoV-2 infection A. Visconti, V. Bataille, N. Rossi, J. Kluk, R. Murphy, S. Puig, et al. (+9)
169 [GO] 2021―Jan―14 COVID-19-associated cutaneous manifestations: does HHV-6 play an etiological role? I. Abadías-Granado, A. Navarro-Bielsa, A.M. Morales-Callaghan, L. Roc, C.C. Suso-Estívalez, M. Povar-Echeverría, Y. Gilaberte
170 [GO] 2021―Jan―10 COVID-19 related dermatosis in November 2019. Could this case be Italy’s patient zero? R. Gianotti, M. Barberis, G. Fellegara, C. Galván-Casas, E. Gianotti
171 [GO] 2020―Dec―24 Risk mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey S.K. Mahil, M. Yates, S.M. Langan, Z.Z.N. Yiu, T. Tsakok, N. Dand, et al. (+37)
172 [GO] 2020―Dec―16 SARS-CoV-2 has not been detected directly by electron microscopy in the endothelium of chilblain lesions: reply from the authors I. Colmenero, C. Santonja, M. Alonso-Riaño, D. Andina, J.L. Rodríguez Peralto, L. Requena, A. Torrelo
173 [GO] 2020―Dec―10 Response to Tembhre et al.: ‘Enhanced expression of ACE2 in psoriatic skin and its upregulation in keratinocytes by interferon-gamma: Implication of inflammatory milieu in skin tropism of SARS-CoV-2’ J.R. Gehlhausen, C.J. Ko, W. Damsky
174 [GO] 2020―Dec―04 Association of skin diseases, biological treatment and COVID-19 during the first wave of the pandemic M.A. Descalzo, I. Garcia-Doval
175 [GO] 2020―Nov―29 Impaired type I interferon response in SARS-CoV-2 infection: looking through the cutaneous window D. Bessis
176 [GO] 2020―Nov―06 Enhanced expression of ACE2 in psoriatic skin and its upregulation in keratinocytes by interferon-gamma: Implication of inflammatory milieu in skin tropism of SARS-CoV-2 M.K. Tembhre, A.S. Parihar, V.K. Sharma, S. Imran, N. Bhari, R. Lakshmy, A. Bhalla
177 [GO] 2020―Nov―05 Response to “Reduction in skin cancer diagnosis, and overall cancer referrals, during the COVID-19 pandemic” G. Murray, D. Roche, A. Ridge, C. Hackett, A.M. Tobin
178 [GO] 2020―Nov―03 Oral vesiculobullous lesions as an early sign of COVID-19: immunohistochemical detection of SARS-CoV-2 spike protein C.D. Soares, A. Mosqueda-Taylor, M.G.F. Carvalho, O.P. Almeida
179 [GO] 2020―Nov―02 在 COVID-19 疫情期间观察到的大多数冻疮与 COVID-19 感染无关
180 [GO] 2020―Nov―02 Most chilblains observed during the COVID-19 outbreak are not linked to COVID-19 infection
181 [GO] 2020―Oct―28 Occupational dermatoses during the Covid-19 pandemic: a multicentre audit in the UK and Ireland H. O’Neill, I. Narang, D.A. Buckley, T.A. Phillips, C.G. Bertram, T.O. Bleiker, et al. (+9)
182 [GO] 2020―Oct―26 Prurigo pigmentosa and new-onset type 1 diabetes in a black female patient testing positive for SARS-CoV-2 IgG K.M. Derrick, D.R. Mazori, E.R. Heilman, S.A. Glick
183 [GO] 2020―Oct―05 SARS-CoV-2 导致冠状病毒脚趾
184 [GO] 2020―Oct―05 SARS-CoV-2 causes Covid Toes
185 [GO] 2020―Oct―01 SARS-CoV-2 Has Not Been Detected Directly by Electron Microscopy in the Endothelium of Chilblain Lesions: reply from authors I. Colmenero, C. Santonja, M. Alonso-Riaño, D. Andina, J.L. Rodríguez Peralto, L. Requena, A. Torrelo
186 [GO] 2020―Oct―01 SARS-CoV-2 Has Not Been Detected Directly by Electron Microscopy in the Endothelium of Chilblain Lesions J.K. Brealey, S.E. Miller
187 [GO] 2020―Sep―25 Response to ‘No evidence of SARS-CoV-2 infection by polymerase chain reaction or serology in children with pseudo-chilblain’. Reply from the authors D. Caselli, M. Chironna, D. Loconsole, M. Aricò
188 [GO] 2020―Sep―24 Prevalence of mucocutaneous manifestations, oral and palmoplantar findings in 666 patients with COVID-19 in a field hospital in Spain A. Nuno-Gonzalez, P. Martin-Carrillo, K. Magaletsky, M.D. Martin Rios, C. Herranz Mañas, J. Artigas Almazan, et al. (+11)
189 [GO] 2020―Sep―03 A review of studies into skin symptoms of COVID-19
190 [GO] 2020―Sep―03 COVID-19 皮肤症状研究综述
191 [GO] 2020―Sep―02 Association of COVID-19 with skin diseases and relevant biologics: a cross-sectional study using nationwide claim data in South Korea S.I. Cho, Y.E. Kim, S.J. Jo
192 [GO] 2020―Sep―01 COVID-19 Session
193 [GO] 2020―Sep―01 Illuminating, through immunohistochemistry, the link between SARS-CoV-2 and pernio (chilblains) D.A. Wetter
194 [GO] 2020―Aug―31 Paucity of COVID-19 Dermatology Literature from Low- and Middle-Income Countries R.S. Pendse, B.L. Schwartz, J.L. Jia, E.E. Bailey
195 [GO] 2020―Aug―28 COVID-19 in hidradenitis suppurativa patients X.T. Lima, M.A. Cueva, M.B. Alora
196 [GO] 2020―Aug―28 Response to “No evidence of SARS-CoV-2 infection by PCR or serology in children with pseudochilblain” S. Recalcati, S. Tonolo, F. Luzzaro, F. Fantini
197 [GO] 2020―Aug―15 Chilblains and COVID-19: why SARS-CoV-2 endothelial infection is questioned M. Baeck, D. Hoton, L. Marot, A. Herman
198 [GO] 2020―Aug―15 Chilblains and COVID-19: why SARS-CoV-2 endothelial infection is questioned: reply from authors I. Colmenero, C. Santonja, M. Alonso-Riaño, D. Andina, J.L. Rodríguez-Peralto, L. Requena, A. Torrelo
199 [GO] 2020―Aug―13 Co-Reactivation of Human Herpesvirus alpha Subfamily (HSV Ⅰ and VZV) in Critically Ill Patient with COVID-19 R. Xu, Y. Zhou, L. Cai, L. Wang, J. Han, X. Yang, et al. (+4)
200 [GO] 2020―Aug―13 Occupational Dermatology in the time of the Covid-19 pandemic: A report of experience from London and Manchester, United Kingdom F.J. Ferguson, G. Street, L. Cunningham, I.R. White, J.P. McFadden, J. Williams
201 [GO] 2020―Aug―13 Negative tests for SARS-CoV-2 infection do not rule out its responsibility for chilblains G. Battesti, V. Descamps Vincent
202 [GO] 2020―Aug―13 Negative tests for SARS-CoV-2 infection do not rule out its responsibility for chilblains: reply from authors L. Le Cleach, S. Fourati, E. Sbidian, M. Beylot-Barry
203 [GO] 2020―Jul―31 Cutaneous signs in SARS CoV-2 infection: A plea for more rigorous peer-review in the time of COVID-19 H. Kittler, P. Tschandl, W. Weninger
204 [GO] 2020―Jul―23 A Very Peculiar Practice: Dermatology in the era of Covid-19 S. Walsh, D. Creamer
205 [GO] 2020―Jul―22 The differing pathophysiologies that underlie COVID-19 associated perniosis and thrombotic retiform purpura: a case series C. Magro, J.J. Mulvey, J. Laurence, S. Sanders, N. Crowson, M. Grossman, et al. (+2)
206 [GO] 2020―Jul―22 High incidence of hand eczema in Danish school children following intensive hand hygiene during the COVID-19 pandemic - a nationwide questionnaire study A.B. Simonsen, I.F. Ruge, A.S. Q꫞, J.D. Johansen, J.P. Thyssen, C. Zachariae
207 [GO] 2020―Jul―06 Most chilblains observed during the COVID-19 outbreak occur in patients who are negative for COVID-19 on PCR and serology testing L. Le Cleach, L. Dousset, H. Assier, S. Fourati, S. Barbarot, C. Boulard, et al. (+15)
208 [GO] 2020―Jul―02 Identificadas las principales manifestaciones en la piel de la COVID-19
209 [GO] 2020―Jul―02 COVID-19 确诊患者的五种常见皮肤表现
210 [GO] 2020―Jul―02 Response to: “Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases”: Vesicular eruption in COVID-19 - to exclude varicella S.Y.D. Lim, H.L. Tey
211 [GO] 2020―Jul―02 “Vesicular eruption in COVID-19 - to exclude varicella”: reply from the authors A. Català, C. Galván Casas, G. Carretero Hernández, I. García-Doval
212 [GO] 2020―Jul―02 Five common skin manifestations of COVID-19 identified
213 [GO] 2020―Jul―02 Chilblain-like lesions during COVID-19 pandemic: a serological study on a case series L. Rizzoli, L. Collini, M. Magnano, S. Termine, R. Barcelli, S.D. Infusino, et al. (+4)
214 [GO] 2020―Jul―02 No evidence of SARS-Cov-2 infection by PCR or serology in children with pseudochilblain D. Caselli, M. Chironna, D. Loconsole, L. Nigri, F. Mazzotta, D. Bonamonte, M. Aricò
215 [GO] 2020―Jun―29 Global Hidradenitis Suppurativa COVID-19 Registry: A Registry to Inform Data-Driven Management Practices H.B. Naik, R. Alhusayen, J. Frew, S. Guilbault, J.R. Ingram, M.A. Lowes, et al. (+4)
216 [GO] 2020―Jun―25 COVID-19 chilblain-like lesion: immunohistochemical demonstration of SARS-CoV-2 spike protein in blood vessel endothelium and sweat gland epithelium in a PCR-negative patient C. Santonja, F. Heras, L. Núñez, L. Requena
217 [GO] 2020―Jun―22 Sars-CoV-2 infection: the same virus can cause different cutaneous manifestations: reply from authors C. Galván-Casas, A. Catalá, G. Carretero Hernández, I. Garcia-Doval
218 [GO] 2020―Jun―20 SARS-CoV-2 endothelial infection causes COVID-19 chilblains: histopathological, immunohistochemical and ultraestructural study of 7 paediatric cases I. Colmenero, C. Santonja, M. Alonso-Riaño, L. Noguera-Morel, A. Hernández-Martín, D. Andina, et al. (+4)
219 [GO] 2020―Jun―17 SARS-CoV-2 infection: the same virus can cause different cutaneous manifestations: reply from the authors C. Galván Casas, A. Català, G. Carretero Hernández, I. García-Doval
220 [GO] 2020―Jun―15 Risk of infections in psoriasis. A lesson to learn during the SARS -CoV-2 pandemic L. Naldi
221 [GO] 2020―Jun―13 Sars-CoV-2 infection: the same virus can cause different cutaneous manifestations F. Drago, G. Ciccarese, A. Rebora, S.I. Muzic, A. Parodi
222 [GO] 2020―Jun―05 Reduction in skin cancer diagnosis, and overall cancer referrals, during the COVID-19 pandemic C.H. Earnshaw, H.J.A. Hunter, E. McMullen, C.E.M. Griffiths, R.B. Warren
223 [GO] 2020―Jun―01 Bullous skin disease patients in a high-epidemic COVID-19 area, Bergamo, Italy A. Carugno, P. Sena, F. Raponi, E. Robustelli Test, P. Vezzoli
224 [GO] 2020―Jun―01 Cutaneous manifestations in patients with COVID-19: A preliminary review of an emerging issue A.V. Marzano, N. Cassano, G. Genovese, C. Moltrasio, G.A. Vena
225 [GO] 2020―Jun―01 Emergency management of 2019 novel coronavirus: implications for the dermatology department J. Tao, Z. Song, L. Yang, C. Huang, A. Feng, X. Man
226 [GO] 2020―May―29 Absence of Skin of Colour Images in Publications of COVID-19 Skin Manifestations J.C. Lester, J.L. Jia, L. Zhang, G.A. Okoye, E. Linos
227 [GO] 2020―May―29 Virtual melanoma checks during a pandemic M. Janda, S.M. Swetter, C. Horsham, H.P. Soyer
228 [GO] 2020―May―27 Further evidence that chilblains are a cutaneous manifestation of COVID-19 infection M. Hughes, S. Rogers, G. Lepri, C. Bruni, M. Matucci-Cerinic
229 [GO] 2020―May―14 Thrombotic occlusive vasculopathy in skin biopsy from a livedoid lesion of a COVID-19 patient M. Llamas-Velasco, P. Muñoz-Hernández, J. Lázaro-González, A. Reolid-Pérez, B. Abad-Santamaría, J. Fraga, E. Daudén-Tello
230 [GO] 2020―Apr―30 Cutaneous lesions in a patient with COVID-19: are they related? B. Ahouach, S. Harant, A. Ullmer, P. Martres, E. Bégon, L. Blum, et al. (+2)
231 [GO] 2020―Apr―29 Global reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic S.K. Mahil, Z.Z.N. Yiu, K.J. Mason, N. Dand, B. Coker, D. Wall, et al. (+16)
232 [GO] 2020―Apr―29 Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases C. Galván Casas, A. Català, G. Carretero Hernández, P. Rodríguez-Jiménez, D. Fernández Nieto, A. Rodríguez-Villa Lario, et al. (+19)
233 [GO] 2020―Apr―28 The impact of COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biologic therapy: the Northern Italy experience P. Gisondi, P. Facheris, P. Dapavo, S. Piaserico, A. Conti, L. Naldi, et al. (+3)
234 [GO] 2020―Apr―17 Phototherapeutic approach to dermatological patients during the 2019 Coronavirus pandemic: Real-life Data from the Italian Red Zone A. Pacifico, M. Ardigò, P. Frascione, G. Damiani, A. Morrone
235 [GO] 2020―Apr―07 Adverse Skin Reactions Among Healthcare Workers During the Coronavirus Disease 2019 Outbreak: A Survey in Wuhan and Its Surrounding Regions P. Lin, S. Zhu, Y. Huang, L. Li, J. Tao, T. Lei, et al. (+17)
236 [GO] 2020―Mar―06 Emergency management for preventing and controlling nosocomial infection of 2019 novel coronavirus: implications for the dermatology department J. Tao, Z. Song, L. Yang, C. Huang, A. Feng, X. Man
 [1] 

236 Results       Page 1


[de][en]

Last change 2025―Jul―29 14:55:09 UTC

© Daten-Quadrat 2022       Done in 0.008 sec